276 related articles for article (PubMed ID: 33536467)
21. Downregulation of Mdm2 and Mdm4 enhances viral gene expression during adenovirus infection.
Yang H; Zheng Z; Zhao LY; Li Q; Liao D
Cell Cycle; 2012 Feb; 11(3):582-93. PubMed ID: 22262167
[TBL] [Abstract][Full Text] [Related]
22. Estrogen receptor alpha (ERα/ESR1) mediates the p53-independent overexpression of MDM4/MDMX and MDM2 in human breast cancer.
Swetzig WM; Wang J; Das GM
Oncotarget; 2016 Mar; 7(13):16049-69. PubMed ID: 26909605
[TBL] [Abstract][Full Text] [Related]
23. Mouse models of Mdm2 and Mdm4 and their clinical implications.
Xiong S
Chin J Cancer; 2013 Jul; 32(7):371-5. PubMed ID: 23327795
[TBL] [Abstract][Full Text] [Related]
24. The long and the short of it: the MDM4 tail so far.
Haupt S; Mejía-Hernández JO; Vijayakumaran R; Keam SP; Haupt Y
J Mol Cell Biol; 2019 Mar; 11(3):231-244. PubMed ID: 30689920
[TBL] [Abstract][Full Text] [Related]
25. Increased efficacy of CDDP in a xenograft model of hepatoblastoma using the apoptosis sensitizer ABT-737.
Lieber J; Dewerth A; Wenz J; Kirchner B; Eicher C; Warmann SW; Fuchs J; Armeanu-Ebinger S
Oncol Rep; 2013 Feb; 29(2):646-52. PubMed ID: 23229825
[TBL] [Abstract][Full Text] [Related]
26. Recent Progress and Clinical Development of Inhibitors that Block MDM4/p53 Protein-Protein Interactions.
Zhang S; Lou J; Li Y; Zhou F; Yan Z; Lyu X; Zhao Y
J Med Chem; 2021 Aug; 64(15):10621-10640. PubMed ID: 34286973
[TBL] [Abstract][Full Text] [Related]
27. Ubiquitin-specific protease 2a stabilizes MDM4 and facilitates the p53-mediated intrinsic apoptotic pathway in glioblastoma.
Wang CL; Wang JY; Liu ZY; Ma XM; Wang XW; Jin H; Zhang XP; Fu D; Hou LJ; Lu YC
Carcinogenesis; 2014 Jul; 35(7):1500-9. PubMed ID: 24445145
[TBL] [Abstract][Full Text] [Related]
28. CXCR4 antagonism sensitizes cancer cells to novel indole-based MDM2/4 inhibitors in glioblastoma multiforme.
Daniele S; La Pietra V; Piccarducci R; Pietrobono D; Cavallini C; D'Amore VM; Cerofolini L; Giuntini S; Russomanno P; Puxeddu M; Nalli M; Pedrini M; Fragai M; Luchinat C; Novellino E; Taliani S; La Regina G; Silvestri R; Martini C; Marinelli L
Eur J Pharmacol; 2021 Apr; 897():173936. PubMed ID: 33581134
[TBL] [Abstract][Full Text] [Related]
29. A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network.
Toledo F; Krummel KA; Lee CJ; Liu CW; Rodewald LW; Tang M; Wahl GM
Cancer Cell; 2006 Apr; 9(4):273-85. PubMed ID: 16616333
[TBL] [Abstract][Full Text] [Related]
30. MDM4 is a rational target for treating breast cancers with mutant p53.
Miranda PJ; Buckley D; Raghu D; Pang JB; Takano EA; Vijayakumaran R; Teunisse AF; Posner A; Procter T; Herold MJ; Gamell C; Marine JC; Fox SB; Jochemsen A; Haupt S; Haupt Y
J Pathol; 2017 Apr; 241(5):661-670. PubMed ID: 28097652
[TBL] [Abstract][Full Text] [Related]
31. Targeting p53 for the treatment of cancer.
Duffy MJ; Synnott NC; O'Grady S; Crown J
Semin Cancer Biol; 2022 Feb; 79():58-67. PubMed ID: 32741700
[TBL] [Abstract][Full Text] [Related]
32. Down-regulation of dishevelled-2 inhibits cell proliferation and invasion in hepatoblastoma.
Huang S; Chen J; Tian R; Wang J; Xie C; Gao H; Shan Y; Hong J; Zhang Z; Xu M; Gu S
Pediatr Blood Cancer; 2018 Jul; 65(7):e27032. PubMed ID: 29528187
[TBL] [Abstract][Full Text] [Related]
33. Targeting the MDM2/MDM4 interaction interface as a promising approach for p53 reactivation therapy.
Pellegrino M; Mancini F; Lucà R; Coletti A; Giacchè N; Manni I; Arisi I; Florenzano F; Teveroni E; Buttarelli M; Fici L; Brandi R; Bruno T; Fanciulli M; D'Onofrio M; Piaggio G; Pellicciari R; Pontecorvi A; Marine JC; Macchiarulo A; Moretti F
Cancer Res; 2015 Nov; 75(21):4560-72. PubMed ID: 26359458
[TBL] [Abstract][Full Text] [Related]
34. MDM4 expression in fibrolamellar hepatocellular carcinoma.
Karki A; Putra J; Kim SS; Laquaglia MJ; Perez-Atayde AR; Sadri-Vakili G; Vakili K
Oncol Rep; 2019 Oct; 42(4):1487-1496. PubMed ID: 31322272
[TBL] [Abstract][Full Text] [Related]
35. Mutual regulation of MDM4 and TOP2A in cancer cell proliferation.
Liu T; Zhang H; Yi S; Gu L; Zhou M
Mol Oncol; 2019 May; 13(5):1047-1058. PubMed ID: 30672125
[TBL] [Abstract][Full Text] [Related]
36. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
[TBL] [Abstract][Full Text] [Related]
37. Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development.
Xiong S; Van Pelt CS; Elizondo-Fraire AC; Liu G; Lozano G
Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3226-31. PubMed ID: 16492743
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of Retinoblastoma Cell Growth by CEP1347 Through Activation of the P53 Pathway.
Togashi K; Okada M; Suzuki S; Sanomachi T; Seino S; Yamamoto M; Yamashita H; Kitanaka C
Anticancer Res; 2020 Sep; 40(9):4961-4968. PubMed ID: 32878784
[TBL] [Abstract][Full Text] [Related]
39. miR-33a inhibits cell growth in renal cancer by downregulation of MDM4 expression.
Jiang K; Sun F; Zhu J; Luo G; Ban Y; Zhang P
Mol Genet Genomic Med; 2019 Aug; 7(8):e833. PubMed ID: 31250570
[TBL] [Abstract][Full Text] [Related]
40. High Mdm4 levels suppress p53 activity and enhance its half-life in acute myeloid leukaemia.
Tan BX; Khoo KH; Lim TM; Lane DP
Oncotarget; 2014 Feb; 5(4):933-43. PubMed ID: 24659749
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]